Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity
Authors:ID Khurshed, Mohammed (Author)
ID Aarnoudse, Niels (Author)
ID Hulsbos, Renske (Author)
ID Hira, Vashendriya V. V. (Author)
ID Laarhoven, Hanneke WM van (Author)
ID Wilmink, Johanna W (Author)
ID Molenaar, Remco J. (Author)
ID Noorden, Cornelis J. F. van (Author)
Files:URL URL - Source URL, visit https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.201800547R
 
.pdf PDF - Presentation file, download (1,49 MB)
MD5: 9A19264B3391250C1485FE6AE3EB5ADE
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo NIB - National Institute of Biology
Abstract:Isocitrate dehydrogenase (IDH1)-1 is mutated in various types of human cancer, and the presence of this mutation is associated with improved responses to irradiation and chemotherapy in solid tumor cells. Mutated IDH1 (IDH1MUT) enzymes consume NADPH to produce D-2-hydroxyglutarate (D-2HG) resulting in the decreased re ducing power needed for detoxification of reactive oxygen species (ROS), for example. The objective of the current study was to investigate the mechanism behind the chemosensitivity of the widely used anticancer agent cisplatin in IDH1MUT cancer cells. Oxidative stress, DNA damage, and mitochondrial dysfunction caused by cisplatin treatment were monitored in IDH1MUT HCT116 colorectal cancer cells and U251 glioma cells. We found that exposure to cisplatin induced higher levels of ROS, DNA double-strand breaks (DSBS), and cell death in IDH1MUT cancer cells, as compared with IDH1 wild-type (IDH1WT) cells. Mechanistic investigations revealed that cisplatin treatment dose dependently reduced oxidative respiration in IDH1MUT cells, which was accompanied by disturbed mitochondrial proteostasis, indicative of impaired mitochondrial activity. These effects were abolished by the IDH1MUT inhibitor AGI-5198 and were restored by treatment with D-2HG. Thus, our study shows that altered oxidative stress responses and a vulnerable oxidative metabolism underlie the sensitivity of IDH1MUT cancer cells to cisplatin.—Khurshed, M., Aarnoudse, N., Hulsbos, R., Hira, V. V. V., van Laarhoven, H. W. M., Wilmink, J. W., Molenaar, R. J., van Noorden, C. J. F. IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity. 32, 6344–6352 (2018). www.fasebj.org
Keywords:isocitrate dehydrogenase, chemosensitivity, cis-diamminedichloroplatinum, 2-hydroxyglutarate
Publication status:Published
Publication version:Version of Record
Publication date:01.11.2018
Year of publishing:2018
Number of pages:str. 6344-6352
Numbering:Vol. 32
PID:20.500.12556/DiRROS-19658 New window
UDC:577
ISSN on article:0892-6638
DOI:10.1096/fj.201800547R New window
COBISS.SI-ID:40468997 New window
Publication date in DiRROS:24.07.2024
Views:256
Downloads:246
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:The FASEB journal
Shortened title:FASEB J
Publisher:The Federation
ISSN:0892-6638
COBISS.SI-ID:25451520 New window

Document is financed by a project

Funder:Other - Other funder or multiple funders
Funding programme:Dutch Cancer Society
Project number:KWF-UVA 2014–6839, AMC2016.1–10460
Name:Grants

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.

Secondary language

Language:Slovenian
Keywords:izocitrat dehidrogenaza, kemosenzibilnost, cis-diamminedichloroplatinum, 2-hidroksiglutarat


Back